생명과학회지 (Journal of Life Science)

  • 제28권8호
  • /
  • Pages.992-998
  • /
  • 2018
  • /
  • 1225-9918(pISSN)
  • /
  • 2287-3406(eISSN)
한국생명과학회 (Korean Society of Life Science)
권호 표지
DOI QR코드

DOI QR Code

암미세환경에서 종양관련대식세포의 역할

Role of Tumor-associated Macrophage in Tumor Microenvironment

  • 민도식 (부산대학교 자연과학대학 분자생물학과)
  • Min, Do Sik (Department of Molecular Biology, College of Natural Science, Pusan National University)
  • 투고 : 2018.07.26
  • 심사 : 2018.08.22
  • 발행 : 2018.08.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

암세포는 종양의 성장을 지지하는 다양한 성분으로 구성되어 있는 환경에서 자란다. 암미세환경에 존재하는 주요 세포등은 섬유아세포, 내피세포, 면역세포들이며 이들세포들은 암세포들과 서로 소통을 하고 있다 종양조직에 유입된 면역세포중에서 대식세포가 종양미세환경의 주요성분으로서 다양한 면역현상들을 조절한다. 면역세포유입에 의한 암촉진과 항암효과 간의 복잡한 균형은 종양의 성장과 진행에 필요한 만성염증 환경을 생성시킬 수 있다. 대식세포는 M1과 M2 극성화로 규정된 미세환경 신호에 반응하여 기능적으로 다른 프로그램을 작동시킬 수 있다. 종양관련대식세포는 다양한 사이토카인, 케모카인, 단백질분해효소들을 분비함으로써 암 신생혈관형성, 증식, 전이 및 면역억제를 촉진시킨다. 최근에, 종양관련대식세포는 암줄기세포와 상호작용하여 종양의 진행, 전이 및 항암제 내성을 유도하는 것으로 알려져 있다. 종양관련대식세포는 암미세환경을 유지하기위해 면역억제 기능을 획득하며, 종양의 이질성과 가소성의 특성을 갖고 있어 암관련인자 및 감염등의 노출에 의해 서로 다른 극성형질로 리프로그래밍된다. 종양관련대식세포는 기질인자의 자극에 의해 암특이적인 케모카인들을 생성하기 때문에 케모카인은 질병의 활성을 반영하는 바이오마커로 작용할 수 있다. 종양조직에 종양관련대식세포가 많이 유입될수록 환자의 예후가 좋지 않으며 항암치료에 대한 저항성이 생긴다. 따라서 종양에서 대식세포를 표적화하는 항암치료는 유망한 치료전략이 될 수 있다.

Cancer cells grow in an environment composed of various components that supports tumor growth. Major cell types in the tumor microenvironment are fibroblast, endothelial cells and immune cells. All of these cells communicate with cancer cells. Among infiltrating immune cells as an abundant component of solid tumors, macrophages are a major component of the tumor microenvironment and orchestrates various aspects of immunity. The complex balance between pro-tumoral and anti-tumoral effects of immune cell infiltration can create a chronic inflammatory microenvironment essential for tumor growth and progression. Macrophages express different functional programs in response to microenvironmental signals, defined as M1 and M2 polarization. Tumor-associated macrophages (TAM) secret many cytokines, chemokines and proteases, which also promote tumor angiogenesis, growth, metastasis and immunosuppression. TAM have multifaceted roles in the development of many tumor types. TAM also interact with cancer stem cells. This interaction leads to tumorigenesis, metastasis, and drug resistance. TAM obtain various immunosuppressive functions to maintain the tumor microenvironment. TAM are characterized by their heterogeneity and plasticity, as they can be functionally reprogrammed to polarized phenotypes by exposure to cancer-related factors, stromal factors, infections, or even drug interventions. Because TAMs produce tumor-specific chemokines by the stimulation of stromal factors, chemokines might serve as biomarkers that reflect disease activity. The evidence has shown that cancer tissues with high infiltration of TAM are associated with poor patient prognosis and resistance to therapies. Targeting of TAM in tumors is considered a promising therapeutic strategy for anti-cancer treatment.

키워드

참고문헌

  1. Adeegbe, D. O. and Nishikawa, H. 2013. Natural and induced T regulatory cells in cancer. Front. Immunol. 4, 190-203.
  2. Ambade, A., Satishchandran, A., Saha, B., Gyongyosi, B., Lowe, P., Kodys, K., Catalano, D. and Szabo, G. 2016. Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-$1{\alpha}$ induced IL-10. Oncoimmunology 5, e1221557. https://doi.org/10.1080/2162402X.2016.1221557
  3. Belai, E. B., de Oliveira, C. E., Gasparoto, T. H., Ramos, R. N., Torres, S. A., Garlet, G. P., Cavassani, K. A., Silva, J. S. and Campanelli, A. P. 2014. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis 35, 424-431. https://doi.org/10.1093/carcin/bgt305
  4. Bingle, L., Brown, N. J. and Lewis, C. E. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265. https://doi.org/10.1002/path.1027
  5. Biswas, S. K. and Mantovani, A. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889-896. https://doi.org/10.1038/ni.1937
  6. Cha, H. R., Lee, J. H., Hensel, J. A., Sawant, A. B., Davis, B. H., Lee, C. M., Deshane, J. S. and Ponnazhagan, S. 2016. Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages. Prostate 76, 624-636. https://doi.org/10.1002/pros.23155
  7. Chen, Y., Zhang, S., Wang, Q. and Zhang, X. 2017. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J. Hematol. Oncol. 10, 36-49. https://doi.org/10.1186/s13045-017-0408-0
  8. Coussens, L. M. and Pollard, J. W. 2011. Leukocytes in mammary development and cancer. Cold Spring Harb. Perspect. Biol. 3, a003285.
  9. De, I., Steffen, M. D., Clark, P. A., Patros, C. J., Sokn, E., Bishop, S. M., Litscher, S., Maklakova, V. I., Kuo, J. S., Rodriguez, F. J. and Collier, L. S. 2016. CSF1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated microglia and macrophages. Cancer Res. 76, 2552-2560. https://doi.org/10.1158/0008-5472.CAN-15-2386
  10. Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W. and Johnson, R. S. 2010. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475. https://doi.org/10.1158/0008-5472.CAN-10-1439
  11. Duraiswamy, J., Freeman, G. J. and Coukos, G. 2013. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900-6912. https://doi.org/10.1158/0008-5472.CAN-13-1550
  12. Gajewski, T. F., Schreiber, H. and Fu, Y. X. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022. https://doi.org/10.1038/ni.2703
  13. Greaves, P. and Gribben, J. G. 2013. The role of B7 family molecules in hematologic malignancy. Blood 121, 734-744. https://doi.org/10.1182/blood-2012-10-385591
  14. Greten, F. R. and Karin, M. 2004. The IKK/NF-kappaB activation pathway- a target for prevention and treatment of cancer. Cancer Lett. 206, 193-199. https://doi.org/10.1016/j.canlet.2003.08.029
  15. Grivennikov, S. I., Greten, F. R. and Karin, M. 2010. Immunity, inflammation, and cancer. Cell 140, 883-899. https://doi.org/10.1016/j.cell.2010.01.025
  16. Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G. Y., Osterreicher, C. H., Hung, K. E., Datz, C., Feng, Y., Fearon, E. R., Oukka, M., Tessarollo, L., Coppola, V., Yarovinsky, F., Cheroutre, H., Eckmann, L., Trinchieri, G. and Karin, M. 2012. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254-258. https://doi.org/10.1038/nature11465
  17. Kong, L., Zhou, Y., Bu., H, Lv, T., Shi, Y. and Yang, J. 2016. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J. Exp. Clin. Cancer Res. 35, 131-142. https://doi.org/10.1186/s13046-016-0412-1
  18. Kuang, D. M., Zhao, Q., Peng, C., Xu, J., Zhang, J. P., Wu, C. and Zheng, L. 2009. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327-1337. https://doi.org/10.1084/jem.20082173
  19. Li, Y., Zheng, Y., Li, T., Wang, Q., Qian, J., Lu, Y., Zhang, M., Bi, E., Yang, M., Reu, F., Yi, Q. and Cai, Z. 2015. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma. Oncotarget 6, 24218-24229.
  20. Loke, P. and Allison, J. P. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA. 100, 5336-5341. https://doi.org/10.1073/pnas.0931259100
  21. Lu, T., Ramakrishnan, R., Altiok, S., Youn, J. I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B. and Gabrilovich, D. 2011. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121, 4015-4029. https://doi.org/10.1172/JCI45862
  22. Ma, R., Ji, T., Chen, D., Dong, W., Zhang, H., Yin, X., Ma, J., Liang, X., Zhang, Y., Shen, G., Quin, X. and Huang, B. 2016. Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression. Oncoimmunology 5, e1118599. https://doi.org/10.1080/2162402X.2015.1118599
  23. Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V. and Chouaib, S. 2014. PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781-790. https://doi.org/10.1084/jem.20131916
  24. Noy, R. and Pollard, J. W. 2014. Tumor-associated macrophage: From mechanisms to therapy. Immunity 41, 866-879. https://doi.org/10.1016/j.immuni.2014.09.021
  25. Poh A. H. and Ernst, M. 2018. Targeting macrophages in Cancer: From Bench to besides. Front Oncol. 8, 49-65. https://doi.org/10.3389/fonc.2018.00049
  26. Qian, B. Z. and Pollard, J. W. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51. https://doi.org/10.1016/j.cell.2010.03.014
  27. Quail, D. F. and Joyce, J. A. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437. https://doi.org/10.1038/nm.3394
  28. Rohan, T. E., Xue, X., Lin, H. M., D'Alfonso, T. M., Ginter, P. S., Oktay, M. H., Robinson, B. D., Ginsberg, M., Gertler, F. B., Glass, A. G., Sparano, J. A., Condeelis, J. S. and Jones, J. G. 2014. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J. Natl. Cancer Inst. 106, 1-11. https://doi.org/10.1093/jnci/dju200
  29. Sharda, D. R., Yu, S., Ray, M., Squadrito, M. L., De Palma, M., Wynn, T. A., Morris, S. M. Jr. and Hankey, P. A. 2011. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 187, 2181-2192. https://doi.org/10.4049/jimmunol.1003460
  30. Teng, F., Tian, W. Y., Wang, Y. M., Zhang, Y. F., Guo, F., Zhao, J., Gao, C. and Xue, F. X. 2016. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J. Hematol. Oncol. 9, 8-23. https://doi.org/10.1186/s13045-015-0231-4
  31. Tripathi, C., Tewari, B. N., Kanchan, R. K., Baghel, K. S., Nautiyal, N., Shrivastava, R., Kaur, H., Bhatt, M. L. and Bhadauria, S. 2014. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 5, 5350-5368.
  32. Wang, H., Shao, Q., Sun, J., Ma, C., Gao, W., Wang, Q., Zhao, L. and Qu, X. 2016. Interactions between colon cancer cells and tumor-infiltrated macrophages depending on cancer cell-derived colony stimulating factor 1. Oncoimmunology 5, e1122157. https://doi.org/10.1080/2162402X.2015.1122157
  33. Yang, L., Wang, F., Wang, L., Huang, L., Wang, J., Zhang, B. and Zhang, Y. 2015. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget 6, 10592-10603.
  34. Zhao, P., Gao, D., Wang, Q., Song, B., Shao, Q., Sun, J., Ji, C., Li, X., Li, P. and Qu, X. 2015. Response gene to complement 32 (RGC-32) expression on M2-polarized and tumor-associated macrophages is M-CSF-dependent and enhanced by tumor-derived IL-4. Cell Mol. Immunol. 12, 692-699. https://doi.org/10.1038/cmi.2014.108